Elena Dozio1, Silvia Briganti2, Alessandra Delnevo3, Elena Vianello4, Federica Ermetici2, Francesco Secchi3, Francesco Sardanelli4,3, Lelio Morricone2, Alexis E Malavazos2, Massimiliano M Corsi Romanelli4,5. 1. Department of Biomedical Sciences for Health, Università degli Studi di Milano, Via Luigi Mangiagalli 31, 20133, Milan, Italy. elena.dozio@unimi.it. 2. Diabetology and Metabolic Disease Unit, I.R.C.C.S. Policlinico San Donato, Via R. Morandi 30, 20097, San Donato Milanese, Milan, Italy. 3. Unit of Radiology, I.R.C.C.S. Policlinico San Donato, Via R. Morandi 30, 20097, San Donato Milanese, Milan, Italy. 4. Department of Biomedical Sciences for Health, Università degli Studi di Milano, Via Luigi Mangiagalli 31, 20133, Milan, Italy. 5. Service of Laboratory Medicine 1- Clinical Pathology, I.R.C.C.S. Policlinico San Donato, Via R. Morandi 30, 20097, San Donato Milanese, Milan, Italy.
Abstract
PURPOSE: Soluble receptor for advanced glycation end products (sRAGE) is a decoy receptor which sequesters RAGE ligands and acts as a cytoprotective agent. To date, it is unclear whether the lower sRAGE levels observed in obesity are a marker of increased overall adiposity or reflect increases in particular fat depots. Therefore, we evaluated in healthy women the relationship among sRAGE and indicators of adiposity, including abdominal visceral (VAT) and epicardial visceral (EAT) adipose tissues, to explore the potential role of sRAGE as an earlier biomarker of cardiometabolic risk. METHODS: Plasma sRAGE levels were quantified by an enzyme-linked immunosorbent assay in 47 healthy women. Total fat mass (FM) and fat-free mass were estimated with bioimpedance analysis. Anthropometric measures and biochemical data were recorded. Subcutaneous adipose tissue, VAT and EAT volumes were measured by magnetic resonance imaging. RESULTS: Obese women had lower sRAGE levels compared to normal-weight women. sRAGE levels were also lower in women with a waist circumference (WC) larger than 80 cm. Correlation analyses indicated an inverse association of sRAGE with body mass index and FM. Concerning adipose tissue distribution, sRAGE inversely correlated with WC, EAT and VAT depots. In a multiple stepwise regression analysis, performed to emphasize the role of fat distribution, EAT volume was the only predictor of sRAGE. CONCLUSIONS: Lower sRAGE levels reflect accumulation of visceral fat mainly at the epicardial level and are present in advance of metabolic complications in adult women. sRAGE quantification might be an early marker of cardiometabolic risk.
PURPOSE: Soluble receptor for advanced glycation end products (sRAGE) is a decoy receptor which sequesters RAGE ligands and acts as a cytoprotective agent. To date, it is unclear whether the lower sRAGE levels observed in obesity are a marker of increased overall adiposity or reflect increases in particular fat depots. Therefore, we evaluated in healthy women the relationship among sRAGE and indicators of adiposity, including abdominal visceral (VAT) and epicardial visceral (EAT) adipose tissues, to explore the potential role of sRAGE as an earlier biomarker of cardiometabolic risk. METHODS: Plasma sRAGE levels were quantified by an enzyme-linked immunosorbent assay in 47 healthy women. Total fat mass (FM) and fat-free mass were estimated with bioimpedance analysis. Anthropometric measures and biochemical data were recorded. Subcutaneous adipose tissue, VAT and EAT volumes were measured by magnetic resonance imaging. RESULTS: Obese women had lower sRAGE levels compared to normal-weight women. sRAGE levels were also lower in women with a waist circumference (WC) larger than 80 cm. Correlation analyses indicated an inverse association of sRAGE with body mass index and FM. Concerning adipose tissue distribution, sRAGE inversely correlated with WC, EAT and VAT depots. In a multiple stepwise regression analysis, performed to emphasize the role of fat distribution, EAT volume was the only predictor of sRAGE. CONCLUSIONS: Lower sRAGE levels reflect accumulation of visceral fat mainly at the epicardial level and are present in advance of metabolic complications in adult women. sRAGE quantification might be an early marker of cardiometabolic risk.
Authors: A Bierhaus; S Schiekofer; M Schwaninger; M Andrassy; P M Humpert; J Chen; M Hong; T Luther; T Henle; I Klöting; M Morcos; M Hofmann; H Tritschler; B Weigle; M Kasper; M Smith; G Perry; A M Schmidt; D M Stern; H U Häring; E Schleicher; P P Nawroth Journal: Diabetes Date: 2001-12 Impact factor: 9.461
Authors: Guido A Rosito; Joseph M Massaro; Udo Hoffmann; Frederick L Ruberg; Amir A Mahabadi; Ramachandran S Vasan; Christopher J O'Donnell; Caroline S Fox Journal: Circulation Date: 2008-01-22 Impact factor: 29.690
Authors: A Ojima; T Matsui; N Nakamura; Y Higashimoto; S Ueda; K Fukami; S Okuda; S Yamagishi Journal: Horm Metab Res Date: 2014-08-08 Impact factor: 2.936
Authors: Edwin R Miranda; Vikram S Somal; Jacob T Mey; Brian K Blackburn; Edward Wang; Sarah Farabi; Kristian Karstoft; Ciaran E Fealy; Sangeeta Kashyap; John P Kirwan; Laurie Quinn; Thomas P J Solomon; Jacob M Haus Journal: Am J Physiol Endocrinol Metab Date: 2017-08-15 Impact factor: 4.310
Authors: E R Miranda; K N Z Fuller; R K Perkins; C M Kroeger; J F Trepanowski; K A Varady; J M Haus Journal: Nutr Metab Cardiovasc Dis Date: 2018-08-02 Impact factor: 4.222
Authors: Beatriz Paradela-Dobarro; Ángel Fernández-Trasancos; Diana Bou-Teen; Sonia Eiras; Rocío González-Ferreiro; Rosa M Agra; Alfonso Varela-Román; Ana I Castro-Pais; Marcos C Carreira; Felipe F Casanueva; Ezequiel Álvarez; José R González-Juanatey Journal: Cardiovasc Diabetol Date: 2017-09-15 Impact factor: 9.951
Authors: Kelly N Z Fuller; Edwin R Miranda; John P Thyfault; Jill K Morris; Jacob M Haus Journal: Mediators Inflamm Date: 2018-02-22 Impact factor: 4.711